Pluri Inc.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Work to develop vaccines and treatments for COVID-19 is continuing around the world. Companies are joining forces to boost their efforts, and progress is being made on the research front. Meanwhile, t

Ridgeback To Lead Development Of Emory University Viral Replication Inhibitor Privately held Ridgeback Biotherapeutics LP and Emory University y announced on 19 March they will work together to advan

Biopharmaceutical companies continue to buck the broader trend of initial public offerings being on hold with ORIC Pharmaceuticals Inc. as the latest company to launch an IPO despite ongoing economi